- Home
- OLP vs PROK Comparison
OLP vs PROK Comparison
Compare OLP & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- PROK
- Stock Information
- Founded
- OLP 1982
- PROK 2015
- Country
- OLP United States
- PROK United States
- Employees
- OLP N/A
- PROK N/A
- Industry
- OLP Real Estate Investment Trusts
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OLP Real Estate
- PROK Health Care
- Exchange
- OLP Nasdaq
- PROK Nasdaq
- Market Cap
- OLP 478.2M
- PROK 417.1M
- IPO Year
- OLP N/A
- PROK N/A
- Fundamental
- Price
- OLP $20.79
- PROK $2.21
- Analyst Decision
- OLP
- PROK Strong Buy
- Analyst Count
- OLP 0
- PROK 4
- Target Price
- OLP N/A
- PROK $6.25
- AVG Volume (30 Days)
- OLP 125.6K
- PROK 1.5M
- Earning Date
- OLP 11-06-2025
- PROK 11-10-2025
- Dividend Yield
- OLP 8.64%
- PROK N/A
- EPS Growth
- OLP N/A
- PROK N/A
- EPS
- OLP 1.54
- PROK N/A
- Revenue
- OLP $97,423,000.00
- PROK $744,000.00
- Revenue This Year
- OLP $8.44
- PROK $471.74
- Revenue Next Year
- OLP $3.05
- PROK N/A
- P/E Ratio
- OLP $13.55
- PROK N/A
- Revenue Growth
- OLP 9.29
- PROK N/A
- 52 Week Low
- OLP $19.62
- PROK $0.46
- 52 Week High
- OLP $30.46
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- OLP 52.81
- PROK 39.34
- Support Level
- OLP $20.02
- PROK $2.04
- Resistance Level
- OLP $21.06
- PROK $2.25
- Average True Range (ATR)
- OLP 0.42
- PROK 0.21
- MACD
- OLP 0.10
- PROK -0.03
- Stochastic Oscillator
- OLP 76.44
- PROK 19.23
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.